Trial · NCT00379769
Outcomes53
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 53
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events | Baseline through End of Study (up to 7.5 years) | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | participants | NUMBER |
| SECONDARY | Number of Participants With Cardiovascular Events and All-cause Deaths | Baseline through End of Study (up to 7.5 years) | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | participants | NUMBER |
| SECONDARY | Total Number of Cardiovascular Hospitalisations and Cardiovascular Deaths | Baseline through End of Study (up to 7.5 years) | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | Number of events | NUMBER |
| SECONDARY | Number of Participants With First Cardiovascular Hospitalisations/Cardiovascular Deaths by Stratum | Baseline through End of Study (up to 7.5 years) | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | partcipants | NUMBER |
| SECONDARY | Number of Participants With CV/Microvascular Events | Baseline through End of Study (up to 7.5 years) | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | participants | NUMBER |
| SECONDARY | Number of Participants With Glycaemic Failure Events | Baseline through to end of randomised dual therapy | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | participants | NUMBER |
| SECONDARY | Number of Participants With Addition of Third Oral Agent/Switch to Insulin | Baseline through End of Study (up to 7.5 years) | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | participants | NUMBER |
| SECONDARY | The Number of Participants Starting Insulin at Any Time During the Study | Baseline through End of Study (up to 7.5 years) | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | participants | NUMBER |
| SECONDARY | Model Adjusted Change From Baseline in HbA1c at Month 60 | Baseline and Month 60 of randomised dual therapy treatment period | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | Percent | MEAN |
| SECONDARY | Model Adjusted Change From Baseline in Fasting Plasma Glucose at Month 60 | Baseline to Month 60 of the randomised dual therapy treatment period | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | mmol/L (millimoles/Liter) | MEAN |
| SECONDARY | Model Adjusted Mean Change From Baseline in Insulin and Pro-insulin at Month 60 | Baseline to Month 60 of the randomised dual therapy treatment period | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | picamoles/liter (pmol/L) | MEAN |
| SECONDARY | Number of HbA1c and Fasting Plasma Glucose (FPG) Responders at Month 60 | Baseline to Month 60 of the randomised dual therapy treatment period | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | participants | NUMBER |
| SECONDARY | Model Adjusted Ratio to Baseline (Expressed as a Percentage) Homeostasis Model Assessment (HOMA) Beta Cell Function and Insulin Sensitivity at Month 60 | Baseline to Month 60 of the randomised dual therapy treatment phase | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | percent change | GEOMETRIC_MEAN |
| SECONDARY | Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC), Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Triglycerides, and Free Fatty Acids (FFAs) at Month 60 | Baseline to Month 60 of the randomised dual therapy treatment phase | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | percent change | GEOMETRIC_MEAN |
| SECONDARY | Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC):High-density Lipoprotein (HDL) Cholesterol and Low-density Lipoprotein (LDL) Cholesterol:HDL Cholesterol Ratios at Month 60 | Baseline to Month 60 of the randomised dual therapy treatment period | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | percent change | GEOMETRIC_MEAN |
| SECONDARY | Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Apolipoprotein B (Apo-B) at Month 60 | Baseline to Month 60 of the randomised dual therapy treatment period | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | percent change | GEOMETRIC_MEAN |
| SECONDARY | Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Urinary Albumin Creatinine Ratio at Month 60 | Baseline to Month 60 of the randomised dual therapy treatment phase | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | percent change | GEOMETRIC_MEAN |
| SECONDARY | Model Adjusted Change From Baseline in Body Weight at Month 60 | Baseline to Month 60 of the randomised dual therapy treatment phase | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | kilograms | MEAN |
| SECONDARY | Model Adjusted Change From Baseline in Alanine Aminotransferase at Month 60 | Baseline to Month 60 of the randomised dual therapy treatment phase | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | U/L (Units/Liter) | MEAN |
| SECONDARY | Model Adjusted Change From Baseline in Waist Circumference at Month 60 | Baseline to Month 60 of the randomised dual therapy treatment phase | Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication | cm (centimeters) | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00379769/outcomes